{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-020766","form_type":"8-K","ticker":"RNGE","cik":"0001438943","company_name":"RANGE IMPACT, INC.","filed_at":"2021-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.115568+00:00","generated_at":"2026-06-29T08:37:18.566083+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vitality Biopharma enters $5M equity line at 85% discount with warrants","bullets":["Shares sold at 85% of lowest 5-day VWAP; warrants at 115% of same VWAP.","Drawdowns limited to $250K per notice; financing expires Dec 31, 2022 or $5M total.","Proceeds to advance VBX-100 prodrug preclinical studies and general corporate purposes.","VBX-100 granted FDA Orphan Drug Designation for pediatric ulcerative colitis.","Institutional investor's beneficial ownership capped at 9.99% for shares, 4.99% for warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-020766","json":"https://secwatch.observer/filing/0001493152-21-020766.json","markdown":"https://secwatch.observer/filing/0001493152-21-020766.md","text":"https://secwatch.observer/filing/0001493152-21-020766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438943/000149315221020766/0001493152-21-020766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438943/000149315221020766/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T08:37:18.566083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}